New drug effective, safe in long-term treatment of moderate to severe atopic dermatitis
Patients with moderate to severe atopic dermatitis showed promising results during and up to 20 weeks after treatment in a clinical trial evaluating rocatinlimab, according to a study. “I think [rocatinlimab] will be the next huge, big advance,” Emma Guttman-Yassky, MD, PhD, the Waldman Professor and System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the
Source: healio.com